This page lists the SEC filings reported by Baker Brothers Advisors.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13D/A | 2023-12-20 | BAKER BROS. ADVISORS LP | Neurogene Inc. | 649,572 | 5.0% | EDGAR |
| SC 13D/A | 2023-12-18 | BAKER BROS. ADVISORS LP | Seagen Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2023-12-15 | BAKER BROS. ADVISORS LP | IGM Biosciences, Inc. | 3,744,669 | 11.4% | EDGAR |
| SC 13D/A | 2023-12-13 | BAKER BROS. ADVISORS LP | Prelude Therapeutics Inc | 10,222,968 | 24.3% | EDGAR |
| SC 13D/A | 2023-11-24 | BAKER BROS. ADVISORS LP | BELLICUM PHARMACEUTICALS, INC | 2,365,472 | 20.0% | EDGAR |
| SC 13D/A | 2023-11-21 | BAKER BROS. ADVISORS LP | MADRIGAL PHARMACEUTICALS, INC. | 1,987,702 | 10.0% | EDGAR |
| SC 13D/A | 2023-11-14 | BAKER BROS. ADVISORS LP | BeiGene, Ltd. | 138,222,377 | 10.2% | EDGAR |
| SC 13G/A | 2023-11-13 | BAKER BROS. ADVISORS LP | CERUS CORP | 19,082,012 | 10.5% | EDGAR |
| SC 13D/A | 2023-10-10 | BAKER BROS. ADVISORS LP | Neoleukin Therapeutics, Inc. | 1,894,217 | 20.0% | EDGAR |
| SC 13D/A | 2023-10-05 | BAKER BROS. ADVISORS LP | MADRIGAL PHARMACEUTICALS, INC. | 2,015,760 | 10.0% | EDGAR |
| SC 13D/A | 2023-08-17 | BAKER BROS. ADVISORS LP | Neoleukin Therapeutics, Inc. | 9,469,838 | 20.0% | EDGAR |
| SC 13G/A | 2023-08-10 | BAKER BROS. ADVISORS LP | Verastem, Inc. | - | 0.0% | EDGAR |
| SC 13G/A | 2023-08-10 | BAKER BROS. ADVISORS LP | Mereo Biopharma Group plc | 14,604,391 | 2.2% | EDGAR |
| SC 13D/A | 2023-08-08 | BAKER BROS. ADVISORS LP | MADRIGAL PHARMACEUTICALS, INC. | 1,545,113 | 8.4% | EDGAR |
| SC 13D/A | 2023-07-19 | BAKER BROS. ADVISORS LP | Neoleukin Therapeutics, Inc. | 10,040,817 | 20.0% | EDGAR |
| SC 13D/A | 2023-06-28 | BAKER BROS. ADVISORS LP | IGM Biosciences, Inc. | 3,277,567 | 10.0% | EDGAR |
| SC 13D | 2023-06-20 | BAKER BROS. ADVISORS LP | MADRIGAL PHARMACEUTICALS, INC. | 1,545,113 | 8.4% | EDGAR |
| SC 13G/A | 2023-06-12 | BAKER BROS. ADVISORS LP | Verastem, Inc. | 1,345,192 | 8.0% | EDGAR |
| SC 13D/A | 2023-06-02 | BAKER BROS. ADVISORS LP | TScan Therapeutics, Inc. | 2,793,938 | 6.5% | EDGAR |
| SC 13D/A | 2023-05-24 | BAKER BROS. ADVISORS LP | Prelude Therapeutics Inc | 10,219,080 | 19.5% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.